DRMA today
$0.61-$0.05 (-7.70%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $1.72
Key levels
Resistance$1.06
Resistance$0.95
Support$0.60
Latest news & SEC filings
EarningsDermata Therapeutics Posts Q3 2026 Results, Gives Business Update
EarningsDermata Therapeutics reports Q3 EPS of $(0.55), matching expectations
All DRMA news →About Dermata Therapeutics
Dermata Therapeutics is a skincare company developing cosmetic and over-the-counter treatments for common skin conditions. Its products use a processed freshwater sponge ingredient, Spongilla lacustris, marketed as Bioneedle, which is designed to create microchannels in the skin. The company plans to sell its Tome brand products directly to consumers online and to skincare professionals such as dermatologists, med spas, and aestheticians. Its initial offerings target skin renewal and acne.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Dermata Therapeutics, Inc. (DRMA)
What Is the Price Target for DRMA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is DRMA a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 3 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DRMA.
Start Free Trial →Is DRMA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$2.24
12
Moat Score
NONE
2/9
Piotroski Score
-16.0
Altman Z-Score
What Is Smart Money Doing with DRMA?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DRMA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
89.84%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for DRMA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DRMA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:50:30 | $0.63 | 2,000 | $$1K | BUY |
| 17:38:12 | $0.66 | 2,000 | $$1K | BUY |
| 17:37:05 | $0.66 | 3,000 | $$2K | BUY |
| 17:28:01 | $0.66 | 2,453 | $$2K | BUY |
| 17:27:41 | $0.66 | 4,000 | $$3K | BUY |
5 dark pool trades shown · $$9K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Dermata Therapeutics, Inc. (DRMA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DRMA — frequently asked questions
What is DRMA stock price today?
Dermata Therapeutics, Inc. (DRMA) is at $0.61, down 7.70% (-$0.05) at the Nov 13, 2026 close.
Why is DRMA stock moving today?
Latest DRMA news — Nov 11, 2026: Dermata Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 10, 2026: Dermata Therapeutics reports Q3 EPS of $(0.55), matching expectations
Why did DRMA stock move on Oct 15, 2026?
Dermata Therapeutics shares surged 18.41% to close at $0.91 on heavy volume of over 116 million shares, with the stock briefly halted on a circuit breaker to the upside after being up as much as 67.84% intraday. The rally followed the company's announcement that over 71% of patients showed overall skin improvements at Day 29 in its cosmetic clinical trial of Tome Foundational Treatment, with study results also indicating skin appearance improvements.
Did DRMA beat earnings?
DRMA last reported on Aug 11, 2026: EPS -$0.74 vs -$0.55 expected — a miss of 34.5%.
Does DRMA pay a dividend?
DRMA does not currently pay a dividend.
What are DRMA support and resistance levels?
Support: $0.60. Resistance: $0.95, $1.06, $1.18.
What are insiders doing with DRMA?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on DRMA?
Nov 11, 2026: Dermata Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 10, 2026: Dermata Therapeutics reports Q3 EPS of $(0.55), matching expectations